CriticalClass III antiarrhythmics (Vaughan Williams)×Fourth-generation fluoroquinolone
Updated · Methodology
Mechanism
Moxifloxacin prolongs the QT interval on the electrocardiogram (ECG), and the effect may increase with higher drug concentrations and faster intravenous infusion (moxifloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; moxifloxacin label, US Food and Drug Administration, FDA). Amiodarone also prolongs the QT interval, and new arrhythmias during amiodarone treatment usually occur when drug interactions or electrolyte disturbances prolong the interval further (amiodarone SmPC, AEMPS). The Spanish moxifloxacin SmPCs do not rule out an additive effect of the two drugs on the QT interval and link it to a higher risk of ventricular arrhythmias, including torsade de pointes. Rare cases of QT prolongation, with or without torsade de pointes, have been reported in patients taking amiodarone with fluoroquinolones (moxifloxacin and amiodarone SmPCs, AEMPS). The moxifloxacin SmPC considers metabolic interactions through cytochrome P450 enzymes unlikely (AEMPS), so in the documents the risk of this pair comes from the combined effect of the two drugs on the heart. Amiodarone is eliminated very slowly, with a half-life of 15–142 days, so its interactions persist for weeks to months after it is stopped (amiodarone label, FDA).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, fast heartbeat, ventricular tachyarrhythmias, fainting with brief loss of consciousness, torsade de pointes and cardiac arrest have been reported with moxifloxacin (moxifloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label names prolonged palpitations and loss of consciousness as symptoms of QT prolongation (moxifloxacin label, US Food and Drug Administration, FDA). Amiodarone can worsen an existing arrhythmia or cause new ventricular fibrillation, incessant ventricular tachycardia and polymorphic ventricular tachycardia of the torsade de pointes type (amiodarone label, FDA). Women and older people may be more sensitive to QT-prolonging drugs, and low potassium can increase QT prolongation and the risk of torsade de pointes (moxifloxacin and amiodarone SmPCs, AEMPS).
Management
The combination is contraindicated: the Spanish moxifloxacin summaries of product characteristics (SmPCs) name amiodarone among the class III antiarrhythmics that must not be given with moxifloxacin. The SmPC of one Spanish amiodarone generic also names moxifloxacin as contraindicated (moxifloxacin and amiodarone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The original Spanish amiodarone SmPC says to avoid fluoroquinolones during amiodarone treatment (AEMPS). The US amiodarone and moxifloxacin labels say to avoid this combination (amiodarone and moxifloxacin labels, US Food and Drug Administration, FDA). Amiodarone interactions can occur for several months after amiodarone is stopped (AEMPS). Moxifloxacin itself is contraindicated in documented QT prolongation, uncorrected hypokalaemia, clinically relevant bradycardia, heart failure with reduced left ventricular ejection fraction and a history of symptomatic arrhythmias (moxifloxacin SmPC, AEMPS). If signs of arrhythmia appear during moxifloxacin treatment, stop moxifloxacin, even if the electrocardiogram (ECG) shows no changes (AEMPS). Before starting amiodarone, record an ECG, measure blood potassium and correct a potassium deficit (amiodarone SmPC, AEMPS). The US label also says to correct low magnesium and calcium beforehand (FDA). If torsade de pointes occurs, do not give antiarrhythmics. Use ventricular pacing, and intravenous magnesium sulfate can also be given (amiodarone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Moxifloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 656f582c-ecba-4ec8-9420-9562114d889b, version 1, 08/2026, sections 5.6 (QT Prolongation) and 7.5 (Drugs that Prolong QT)
- AEMPS: Ficha técnica: Amiodarona (nº registro 81291), sección 4.5 (2022)– AEMPS, CIMA, nº registro 81291, revisión 06/2022, sección 4.5
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: Pacerone (amiodarone) prescribing information (2025)– FDA, DailyMed setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (Upsher-Smith Laboratories), version 27, revised 07/2025, sections 5.4 and 7 (Table 1)
- AEMPS: Ficha técnica: Moxifloxacino (nº registro 74573), sección 4.5 (2026)– AEMPS, CIMA, nº registro 74573, revisión 03/2026, sección 4.5
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.3 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, secciones 4.3, 4.4, 4.5 y 4.8